Insight Molecular Diagnostics Inc.

About Insight Molecular Diagnostics Inc.

iMDx is a company focused on advancing precision medicine through innovative diagnostics in oncology and transplantation. Their mission is to deliver clear, actionable insights for researchers, clinicians, and healthcare systems, enabling early detection, guiding treatment, and accelerating discovery to drive better decisions across the continuum of care.

Products & Services

GraftAssureCoreTM:A blood-based transplant monitoring test that quantifies donor-derived cell-free DNA (dd-cfDNA) concentration following transplantation.

DetermaCNI:An in-development test to measure genomic copy number instability in circulating tumor DNA for monitoring therapeutic efficacy in cancer patients (coming soon).

DetermaIO:A 27-gene expression laboratory-developed test to assess the tumor microenvironment and predict response likelihood to immunotherapies (coming soon).

OncoTIME:A research-use-only 27-gene expression assay test kit to assess the tumor microenvironment (coming soon).

Specialties

Precision Diagnostics Oncology Transplantation Molecular Diagnostics Cancer Immunotherapy Guidance Transplant Monitoring

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 26000000 MR: - FA: 26.0 million FAN: 26000000	D: 2026-02-11 FD: 2026-02-11	1 investors

Registered Direct Offering Latest

2026-02-11

$26.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Doe

Designer

Recent News